Effect of Astragalus membranaceus on Cosmc expression and IgA dys-glycosylation in IgA Nephropathy
Study ID: TCTR20140515001
Current status: Completed
Last Updated: May 15, 2014
Tracking Information
Date of Registration in Primary Registry: May 15, 2014
Date of First Enrollment: January 01, 2013 (Actual)
Target Sample Size: 21
Last Updated Date: May 15, 2014
Primary Outcome(s):
  • Outcome name:
       Metric/method of measurement: Cosmc gene expression
       Time point:
       Safety Issue?: No


  • Key Secondary Outcomes:
  • Outcome name:
       Metric/method of measurement: IgA glycosylation level
       Time point:
       Safety Issue?: No


  • Descriptive Information
    Public Title: Effect of Astragalus membranaceus on Cosmc expression and IgA dys-glycosylation in IgA Nephropathy
    Scientific Title: Effect of Astragalus membranaceus on Cosmc expression and IgA dys-glycosylation in IgA Nephropathy
    Brief Summary: Blood sample (10ml) was taken from every patient after informed consent was obtained. Lymphocytes were obtained using lymphocyte isolation media. Thereafter, Isolated B Lymphocytes were cultured with or without LPS. Cosmc expression, IgA glycosylation and IgA level were measured then.
    Detailed Description: Objective: Decreased Core I β3-Gal-T-specific molecular chaperone (Cosmc) expression induced IgA1 dys-glycosylation is the main characteristic of IgA nephropathy (IgAN).This study tried to elucidate the effect of Astragalus membranaceus on Cosmc expression and IgA O-glycosylation of peripheral B lymphocytes in IgAN patients.
    Methods: Peripheral B lymphocytes of 21 IgAN patients were isolated and cultured with or without lipopolysaccharide (LPS) and Astragalus membranaceus injection (AMI). Cosmc mRNA and protein expression levels were measured by real-time RT-PCR and Western blot. IgA1 and glycosylation level were determined by ELISA and VV lectin-binding method. Correlation analysis was performed between Cosmc expression levels and IgA1 glycosylation level.
    Study Design: Allocation: N/A
    Control: N/A
    Study Endpoint Classification:
    Intervention Model: No Intervention
    Number of Groups: 1
    Masking: (Masked Roles: )
    Primary Purpose: Basic Science
    Study Phase: N/A
    Health Condition(s) or Problem(s) Studied: IgA nephropathy
    Study Groups:
  • Group: 1
  • Group Name: IgA patients
    Descriptions:
    Recruitment Information
    Recruitment Status: Completed
    Estimated Enrollment: 21
    Study Start Date (First enrollment): January 01, 2013
    Primary Completion Date: June 01, 2013
    Inclusion Criteria:
    Inclusion Criteria
    Gender: Both
    Age Limit: Minimum 18 Years : Maximum 60 Years
    IgA nephropathy
    Exclusion Criteria
    Other disease
    Accept Healthy Volunteers: Yes
    Countries of Recruitment China
    Contact for Public Queries:
    Contact for Public Query's Name: wei qin
    Degree: MD
    Phone: 86-18980602119
    Email: ddqstrike@163.com
    Postal Address: 37# Guoxue Road, Chengdu
    State/Province: sichuan        Postal Code: 610041
    Country: China
    Administrative Information
    Primary Registry Site: Thai Clinical Trials Registry
    Trial Identification Number: TCTR20140515001
    Secondary Identifying Numbers: Nil known
    Source(s) of Monetary or Material Supports: West China Hospital of Sichuan University
    Study Primary Sponsor: West China Hospital of Sichuan University
    Study Secondary Sponsor: 1.) West China Hospital of Sichuan University
    Contact for Scientific Queries:
    Contact for Scientific Query's Name: Wei Qin
    Degree: MD
    Phone: 86-18980602119
    Email: ddqstrike@163.com
    Postal Address: 37# Guoxue Road, West China Hospital of Sichuan University, Chengdu
    State/Province: sichuan        Postal Code: 610041
    Country: China
    Track changes

    Copyright  © 2009. Medical Research Foundation, Thailand. All Rights Reserved.